We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current NVZMF market cap is 25.54B. The company's latest EPS is EUR 0.7377 and P/E is 75.91.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | EUR (€) | EUR (€) | |
| Total Revenue | 14.01B | 14.95B | 17.55B | 2.4B | 3.83B |
| Operating Income | 3.65B | 3.94B | 4.55B | 531.2M | 497.5M |
| Net Income | 2.83B | 3.15B | 3.68B | 405.9M | 305.8M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | EUR (€) | EUR (€) | |
| Total Assets | 20.51B | 24.77B | 27.98B | 3.81B | 15.2B |
| Total Liabilities | 9.27B | 12.56B | 13.76B | 1.88B | 4.02B |
| Total Equity | 11.24B | 12.21B | 14.23B | 1.93B | 11.18B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | EUR (€) | EUR (€) | |
| Operating | 4.36B | 4.06B | 4.01B | 557.1M | 1.02B |
| Investing | -1.52B | -2.75B | -2.67B | -286.2M | -199.7M |
| Financing | -2.31B | -1.59B | -1.25B | -253.5M | -703.2M |
| Market Cap | 25.54B |
| Price to Earnings Ratio | 75.91 |
| Price to Sales Ratio | 6.06 |
| Price to Cash Ratio | 82.91 |
| Price to Book Ratio | 2.08 |
| Dividend Yield | 66.12% |
| Shares Outstanding | 414.56M |
| Average Volume (1 week) | 12.57k |
| Average Volume (1 Month) | 4.03k |
| 52 Week Change | 11.55% |
| 52 Week High | 71.518 |
| 52 Week Low | 53.32 |
| Spread (Intraday) | 9.4 (13.83%) |
| Company Name | Novonesis AS (PK) |
| Address |
biologiens vej 2 kongens lyngby 2800 |
| Website | https://www.novonesis.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
